VIP Peptide: Gut, Brain & Immune Regulation

Meta Description: VIP peptide (vasoactive intestinal peptide) supports gut healing, neuroprotection and immune balance. Learn its mechanisms, CIRS use, dosing and research.

Vasoactive intestinal peptide — VIP — is one of the most widely distributed signaling molecules in the mammalian body, yet it remains one of the least understood by the research-compound community. It was first isolated from the small intestine in 1970 by Said and Mutt, who described it as a "polypeptide with broad biological activity." That phrase has aged well. Five decades of subsequent work have shown VIP acting as a gut hormone, a central neurotransmitter, a vasodilator, a circadian timekeeper, and a potent anti-inflammatory and immunoregulatory agent — often all at once.

This breadth is exactly why VIP→ sits at the intersection of several research conversations that rarely overlap: gut-brain axis signaling, neuroprotection, autoimmune and inflammatory disease models, and the chronic inflammatory response syndrome (CIRS) protocols associated with water-damaged buildings. For researchers, VIP is interesting precisely because it does not behave like a single-target drug. It is a 28-amino-acid messenger that the body already uses to coordinate inflammation, blood flow, and tissue repair across many systems.

This guide explains what VIP is, how its receptors work, the research areas where it has been studied, how dosing is framed in the literature, and — importantly — why VIP is one of the compounds where prerequisites and physiological context matter more than the dose itself. None of what follows is medical advice; it is a survey of the published research literature on a compound sold for laboratory research use only.

What VIP Is

VIP is a 28-amino-acid neuropeptide belonging to the secretin-glucagon superfamily, which also includes PACAP (pituitary adenylate cyclase-activating polypeptide), its closest structural and functional relative. The two peptides share receptors and overlap heavily in biology, which is why the pharmacology literature almost always discusses them together (Harmar et al., 2012).

Anatomically, VIP is produced in two broad compartments. In the gut, it is synthesized by neurons of the enteric nervous system — the so-called "second brain" embedded in the wall of the gastrointestinal tract. There it relaxes smooth muscle, drives intestinal and pancreatic secretion, dilates splanchnic blood vessels, and helps regulate the local immune environment of the gut mucosa. In the central nervous system, VIP is expressed by specific populations of cortical and hypothalamic neurons, most famously in the suprachiasmatic nucleus (SCN), the brain's master circadian clock.

That SCN role is not a footnote. Aton and colleagues (2005) showed that VIP is essential for synchronizing the individual clock neurons of the SCN into a coherent, body-wide rhythm. Animals lacking VIP signaling lose circadian coherence — their internal clocks desynchronize. This single finding hints at how deeply VIP is woven into systemic regulation: a peptide first found in the intestine turns out to be required for the brain to keep time.

VIP is also a developmental signal. Vaccarino and colleagues (2001) reported that VIP deficiency during a critical window of brain development produced lasting consequences, work that has been discussed in the context of neurodevelopmental conditions including autism. The peptide's reach therefore spans the entire lifespan — from shaping the developing brain to maintaining circadian and immune homeostasis in the adult.

What ties these roles together is a consistent biochemical theme: VIP is, at its core, an anti-inflammatory and pro-homeostatic messenger. Wherever it acts, it tends to push the local environment toward vasodilation, secretion, immune tolerance, and tissue protection rather than toward constriction, inflammation, and damage.

Mechanism: VPAC1, VPAC2, and cAMP

VIP exerts its effects through two G-protein-coupled receptors, VPAC1 and VPAC2 (a third related receptor, PAC1, is preferentially activated by PACAP). Couvineau and Laburthe (2012) detail the structure and pharmacology of these VPAC receptors, which are class B GPCRs — the same structural family as the receptors for GLP-1 and PTH.

The downstream logic is straightforward at the level of the cell and rich in consequence at the level of the organism:

• Receptor binding. VIP binds VPAC1 and VPAC2 with high affinity. VPAC1 is enriched in the liver, lung, intestinal epithelium, and many immune cells; VPAC2 is prominent in smooth muscle, the SCN, and distinct immune subsets. The tissue-specific split of these two receptors is part of why VIP can produce different effects in different organs.
• cAMP elevation. Both receptors couple primarily to the Gs protein, activating adenylate cyclase and raising intracellular cyclic AMP (cAMP). Elevated cAMP, acting through protein kinase A and related effectors, is the master switch behind most of VIP's actions — smooth muscle relaxation, fluid secretion, and, critically, the reprogramming of immune cells.
• Anti-inflammatory reprogramming. In immune cells, the cAMP signal triggered by VIP suppresses the production of pro-inflammatory mediators (such as TNF-alpha, IL-6, and IL-12) while promoting anti-inflammatory ones (such as IL-10). The net effect is a shift away from a pro-inflammatory, tissue-damaging immune posture and toward tolerance and resolution.
• Immune modulation and regulatory T cells. Beyond dampening inflammatory cytokines, VIP actively shapes the adaptive immune system. Delgado and colleagues (2005) demonstrated that VIP generates CD4+CD25+ regulatory T cells (Tregs) in vivo — the immune system's "brakes." This is a fundamentally different mechanism from a simple anti-inflammatory: VIP does not just turn down the volume on inflammation, it expands the cell populations that maintain self-tolerance.
• Vasodilation. The "vasoactive" in the name is literal. Through cAMP-driven relaxation of vascular smooth muscle, VIP is a potent vasodilator. This property underlies both its physiological role in regulating blood flow and one of its most relevant safety considerations, discussed below.
• Neuroprotection. In the CNS, VIP and the cAMP pathway it activates have been shown to protect neurons against injury. Bhatt and colleagues (2014) reported VIP-mediated neuroprotection against glutamate excitotoxicity in cortical neurons — a model relevant to stroke, trauma, and neurodegeneration.

The unifying picture is that VIP is a cAMP-elevating, anti-inflammatory, vasodilating, immunoregulatory signal. It does not force a single dramatic effect; it nudges multiple systems toward a calmer, more tolerant, better-perfused, and better-protected state.

Research Areas

CIRS and the Shoemaker Protocol Context

The single most discussed application of VIP in the research-compound and functional-medicine communities is its role in chronic inflammatory response syndrome (CIRS). The most-cited reference here is Shoemaker and colleagues (2013), who reported that intranasal VIP corrected a constellation of inflammatory and hormonal abnormalities in patients with CIRS acquired following exposure to water-damaged buildings.

CIRS, as framed in that literature, is a state of dysregulated innate immune activation — persistently elevated inflammatory markers, hormonal disruption, and a cascade of downstream symptoms — triggered in susceptible individuals by biotoxin exposure. The reasoning behind VIP's use is mechanistically coherent: if VIP is the body's endogenous anti-inflammatory and immunoregulatory switch, then a depleted VIP state might be both a marker and a driver of the syndrome, and restoring VIP signaling might help reset the dysregulated immune response.

The critical point — emphasized in the source protocol itself and repeated here for researchers — is that VIP appears in that protocol as the final step, not the first. It is introduced only after a long sequence of prerequisites has been addressed: removal from the offending environment, treatment of any colonized infections, normalization of specific upstream markers. The protocol treats VIP as a closing move to be applied to a prepared physiology, not a standalone intervention. This sequencing is not arbitrary, and it is the single most important contextual fact about VIP research, returned to under safety below.

Gut-Brain Axis

Because VIP is simultaneously an enteric neuropeptide and a central neurotransmitter, it is almost a textbook molecule for the gut-brain axis. In the gut, VIP regulates motility, secretion, mucosal blood flow, and the immune tone of the intestinal lining. Abad and colleagues (2003) reported therapeutic effects of VIP in the trinitrobenzene sulfonic acid (TNBS) mouse model of Crohn's disease, with VIP reducing the inflammatory damage characteristic of that model. This positions VIP within the broader research interest in inflammatory bowel conditions and intestinal barrier integrity — the same "gut healing" conversation that surrounds peptides such as BPC-157, though VIP's mechanism is distinctly immunoregulatory rather than growth-factor driven.

The same anti-inflammatory signaling that protects the gut wall also reaches the brain, which is what makes VIP attractive to researchers thinking about systemic, bidirectional gut-brain inflammation rather than treating the two compartments in isolation.

Pulmonary and Inflammatory Disease Models

VIP's vasodilatory and anti-inflammatory actions are pronounced in the lung, where VPAC receptors are abundant and where VIP relaxes airway and pulmonary vascular smooth muscle. This has driven research interest in conditions involving airway inflammation and pulmonary vascular tone.

More broadly, VIP has been studied across a range of autoimmune and inflammatory models. Fernandez-Martin and colleagues (2006) reported that VIP prevented experimental autoimmune encephalomyelitis — the standard animal model of multiple sclerosis — by downregulating both the inflammatory and the autoimmune components of the disease. The dual action is the recurring theme: VIP suppresses acute inflammatory mediators while simultaneously expanding the regulatory arm of the immune system. Delgado and Ganea (2003) similarly reported a neuroprotective effect of VIP in a mouse model of Parkinson's disease, and Gozes and Bhatt (2019) have reviewed VIP's trajectory "from anti-aging to Alzheimer's disease," underscoring the peptide's long-running candidacy in neurodegeneration research.

The Intranasal Route

A practical thread running through much of the human-facing VIP literature, including the CIRS work, is the intranasal route of administration. VIP is a peptide and is therefore degraded if swallowed; intranasal delivery bypasses first-pass metabolism and, importantly, offers a more direct path toward the central nervous system along olfactory and trigeminal pathways. For a molecule whose targets include both the airways and the brain, nasal delivery is mechanistically sensible, which is why the intranasal route dominates the applied VIP research rather than subcutaneous injection.

Dosing and Protocol (Research Framing)

The following describes how dosing is framed in the published research literature. It is not a recommendation, and VIP is sold strictly for laboratory research use only.

In the CIRS literature associated with Shoemaker and colleagues (2013), VIP is studied as an intranasal preparation. The framing in that body of work is one of low, divided microgram-range dosing delivered nasally, with the schedule built around the prerequisites described earlier rather than around chasing a maximal dose. The defining feature of the protocol is not the number on the dose — it is the gating: VIP is introduced only into a physiology that has been prepared, and the research framing treats a test dose under observation as the proper first step because of the vasodilatory blood-pressure effect.

Three points define the research framing more than any specific microgram figure:

• Route. Intranasal, reflecting both the molecule's peptide nature and its dual airway/CNS targets.
• Titration. Low and divided, with the literature emphasizing gradual introduction rather than an immediate full schedule.
• Sequencing. VIP follows the prerequisites. In the source protocol it is explicitly the last element, applied only after upstream issues are resolved and after an initial test dose is tolerated.

Researchers studying VIP outside the CIRS context — in gut, pulmonary, or neuroprotection models — will find that the published work is overwhelmingly preclinical and uses routes and doses tailored to the animal model, which do not translate directly to any applied human framing. The honest summary is that VIP lacks the kind of large, dose-ranging human trial data that exists for many pharmaceuticals; its applied dosing framework is largely defined by a single protocol lineage built around context and prerequisites.

Safety and Unknowns

VIP's safety profile is dominated by a single predictable consequence of its mechanism: it is a vasodilator. Because VIP relaxes vascular smooth muscle through cAMP, the most consistently reported acute effect is a drop in blood pressure, sometimes accompanied by flushing, lightheadedness, or a sensation of warmth. This is not an idiosyncratic side effect — it is the expected pharmacology of a vasoactive peptide, and it is why the research framing built around VIP treats an observed initial test dose as the appropriate first exposure. Any research design involving VIP has to account for hemodynamic monitoring; the blood-pressure effect is the headline safety consideration.

The second major theme is the importance of prerequisites in clinical protocols — a point that deserves emphasis because it is unusual among research compounds. In the CIRS protocol literature, VIP is explicitly positioned as the final step, applied only after environmental remediation, treatment of colonizing infections, and normalization of specific upstream markers. The rationale is that introducing a powerful anti-inflammatory and immunoregulatory signal into a body still actively exposed to the inflammatory trigger is, at best, working against an unresolved cause — and the protocol treats certain unresolved conditions as contraindications to introducing VIP at all. For a researcher, the practical lesson is that VIP is a context-dependent compound: its reported behavior is inseparable from the physiological state it is introduced into. Studying VIP without replicating that context is studying a different question.

Beyond blood pressure and sequencing, several genuine unknowns remain. The long-term consequences of sustained exogenous VIP signaling are not well characterized in humans. Because VIP modulates the immune system toward tolerance — expanding regulatory T cells and suppressing inflammatory cytokines — questions about how chronic VIP exposure interacts with normal immune surveillance have not been resolved in the literature. And because VIP is involved in circadian regulation, developmental signaling, and secretion across many organs, the systemic breadth that makes it interesting is also what makes its full off-target profile difficult to map. The body of high-quality, long-duration human safety data is thin relative to the enthusiasm the peptide attracts.

Frequently Asked Questions

What does VIP actually do in the body?

VIP is a 28-amino-acid neuropeptide that acts as a vasodilator, a gut and central neurotransmitter, a circadian regulator, and — most relevant to current research interest — a potent anti-inflammatory and immunoregulatory signal. It works through the VPAC1 and VPAC2 receptors by raising intracellular cAMP, which relaxes smooth muscle and reprograms immune cells toward tolerance, including the generation of regulatory T cells (Delgado et al., 2005).

Why is VIP associated with CIRS and the Shoemaker protocol?

Shoemaker and colleagues (2013) reported that intranasal VIP corrected inflammatory and hormonal abnormalities in patients with CIRS acquired from water-damaged buildings. The mechanistic logic is that CIRS is a state of dysregulated inflammation, and VIP is the body's endogenous anti-inflammatory switch. Crucially, in that protocol VIP is the final step, used only after upstream prerequisites are addressed.

Why is the intranasal route used instead of injection?

VIP is a peptide and would be degraded if swallowed. Intranasal delivery bypasses first-pass metabolism and provides a more direct route toward the central nervous system. Given that VIP's targets include both the airways and the brain, nasal administration is the route that dominates the applied research literature.

What is the main safety concern with VIP?

Its vasodilatory mechanism. VIP reliably lowers blood pressure and can cause flushing or lightheadedness, which is why the research framing treats an observed initial test dose as the appropriate first exposure. This is predictable pharmacology, not an idiosyncratic reaction, and any research design has to plan for hemodynamic monitoring.

Why does the protocol insist on prerequisites before VIP?

Because VIP is a context-dependent compound. Introducing a strong anti-inflammatory and immunoregulatory signal while the body is still exposed to the original inflammatory trigger works against an unresolved cause. The source protocol treats environmental remediation and the normalization of specific upstream markers as prerequisites, and certain unresolved conditions as reasons not to introduce VIP at all.

Is VIP the same as PACAP?

No, but they are close relatives. VIP and PACAP belong to the same peptide superfamily, share the VPAC1 and VPAC2 receptors, and overlap heavily in biology, which is why the pharmacology literature usually discusses them together (Harmar et al., 2012). PACAP additionally activates a third receptor, PAC1, which VIP engages only weakly.

Conclusion

VIP is unusual among research peptides because its defining feature is not a single dramatic effect but its breadth: a 28-amino-acid messenger that the body uses to coordinate inflammation, blood flow, circadian timing, and immune tolerance across the gut and the brain at once. Its mechanism is coherent — VPAC1 and VPAC2 receptors, cAMP elevation, anti-inflammatory cytokine shifts, regulatory T cell generation, vasodilation, and neuroprotection all flow from the same signaling logic — and the preclinical literature spans Crohn's-model gut healing (Abad et al., 2003), multiple sclerosis and Parkinson's models (Fernandez-Martin et al., 2006; Delgado and Ganea, 2003), and neurodegeneration reviews (Gozes and Bhatt, 2019).

For researchers, the two facts that matter most are practical rather than mechanistic. First, VIP is a vasodilator, so its blood-pressure effect is the central safety consideration and the reason a test dose under observation defines the research framing. Second, VIP is a context-dependent compound: the CIRS protocol that anchors its applied human literature treats it as the last step, applied only to a prepared physiology after prerequisites are met. Study VIP without that context and you are studying a different molecule than the one the literature describes. It is a fascinating, broad-acting, and genuinely under-characterized peptide — and one where the surrounding conditions matter at least as much as the compound itself.

VIP→ Browse all compounds

References

1. Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science. 1970;169(3951):1217-1218.
2. Harmar AJ, et al. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol. 2012;166(1):4-17.
3. Couvineau A, Laburthe M. VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins. Br J Pharmacol. 2012;166(1):42-50.
4. Abad C, et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology. 2003;124(4):961-971.
5. Aton SJ, et al. Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons. Nat Neurosci. 2005;8(4):476-483.
6. Bhatt DK, et al. VIP-mediated neuroprotection against glutamate excitotoxicity in cortical neurons. Neuropeptides. 2014;48(5):319-326.
7. Gozes I, Bhatt DK. VIP: from anti-aging to Alzheimer's disease. J Mol Neurosci. 2019;68(3):436-443.
8. Vaccarino FM, et al. VIP deficiency during brain development: relevance to autism. Ann Neurol. 2001;49(6):780-786.
9. Delgado M, et al. Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo. J Leukoc Biol. 2005;78(6):1327-1338.
10. Shoemaker RC, et al. Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired following exposure to water-damaged buildings. Health. 2013;5(3):396-401.
11. Fernandez-Martin A, et al. VIP prevents experimental multiple sclerosis by downregulating both inflammatory and autoimmune components of the disease. Ann NY Acad Sci. 2006;1070:276-281.
12. Delgado M, Ganea D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease. FASEB J. 2003;17(8):944-946.

Disclaimer: This article is for educational and research purposes only. Peptides mentioned are sold for research use. Consult a healthcare professional before beginning any new protocol.